Search Results - "JUNGI, W. F"

Dangerous nutrition by Jungi, W F

Get full text

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer by JUNGI, W. F, BERNHARD, J, HÜRNY, C, SCHMITZ, S.-F. H, HANSELMANN, S, GUSSET, H, PESTALOZZI, D, GOLDHIRSCH, A

“…To assess the efficacy of carboplatin in patients with hormone-refractory prostate cancer in terms of response rate and palliation, the Swiss Group for…”
Get full text

Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82 by Senn, H J, Maibach, R, Castiglione, M, Jungi, W F, Cavalli, F, Leyvraz, S, Obrecht, J P, Schildknecht, O, Siegenthaler, P

“…To compare two adjuvant combination chemotherapies, cyclophosphamide, methotrexate, and fluorouracil (CMF) and chlorambucil, methotrexate, and fluorouracil…”
Get more information

WHO consensus conference on diet and cancer by Meyskens, F L, Jungi, W F, Gerber, M, de Waard, F, Heidemann, E, Heim, M E, Joossens, J-V, Salvini, S, Trichopoulou, A, Varela, G, Wolfram, G

Get full text

Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study by Thürlimann, B, Morant, R, Jungi, W F, Radziwill, A

“…In a prospective dose-escalation study tolerability and effectiveness of repeated infusions with intravenous pamidronate were investigated. A total of 80…”
Get full text

Treatment of ovarian cancer with surgery, short-course chemotherapy and whole abdominal radiation by Buser, K., Bacchi, M., Goldhirsch, A., Greiner, R., Diener, P., Sessa, C., Jungi, W. F., Forni, M., Leyvraz, S., Engeler, V.

“…Background The primary aim was to induce a high number of pCR in early (FIGO IC, JIB + C)-and advanced (FIGO ffl—IV)—stage ovarian cancer with a surgery plus 4…”
Get full text

Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study by Buser, K S, Joss, R A, Piquet, D, Aapro, M S, Cavalli, F, Haefliger, J M, Jungi, W F, Bauer, J, Obrist, R, Brunner, K W

“…The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients. However, the…”
Get more information

Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy by Goldhirsch, A, Greiner, R, Dreher, E, Sessa, C, Krauer, F, Forni, M, Jungi, F W, Brunner, K W, Veraguth, P, Engeler, V

“…Between April 1981 and June 1985, 195 patients with ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) Stages IIB, IIC, III, and IV,…”
Get more information

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer by Thürlimann, B., Beretta, K., Bacchi, M., Castiglione-Gertsch, M., Goldhirsch, A., Jungi, W. F., Cavalli, F., Senn, H.-J., Fey, M., Löhnert, T.

“…Background: In a phase III randomized trial, we compared the effectiveness and tolerability of fadrozole (CGS 16949A), a non-steroidal aromatase inhibitor, to…”
Get full text

Diet to prevent gastrointestinal cancer? by Jungi, W F

Get more information

Anthracycline-carboplatin combination in metastatic breast cancer by THUÊRLIMANN, B, SENN, H. J, JUNGI, W. F

“…In a pilot study a carboplatinu, 250 mg/m2 i.v., and 4-epidoxirubicin, 90 mg/m2 i.v. or mitoxantrone, 10 mg/m2 i.v., combination chemotherapy regimen was…”
Get full text

Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results by Ludwig, H, Cohen, A M, Huber, H, Nachbaur, D, Jungi, W F, Senn, H, Günczler, P, Schüller, J, Eckhardt, S, Seewann, H L

“…The present trial was designed to evaluate whether interferon (IFN) combined with standard induction chemotherapy and/or interferon remission maintenance…”
Get more information

Concurrent Or Sequential Use Of Cytotoxic Chemotherapy And Hormone Treatment In Advanced Breast Cancer: Report Of The Swiss Group For Clinical Cancer Research by Cavalli, F., Beer, M., Martz, G., Jungi, W. F., Alberto, P., Obrecht, J. P., Mermillod, B., Brunner, K. W.

“…In a trial of combined hormone treatment and cytotoxic chemotherapy 464 patients with advanced breast cancer were randomly allocated to either concurrent or…”
Get full text

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88 by Thürlimann, B, Beretta, K, Bacchi, M, Castiglione-Gertsch, M, Goldhirsch, A, Jungi, W F, Cavalli, F, Senn, H J, Fey, M, Löhnert, T

“…In a phase III randomized trial, we compared the effectiveness and tolerability of fadrozole (CGS 16949A), a non-steroidal aromatase inhibitor, to tamoxifen as…”
Get full text

Etoposide single-agent chemotherapy for solid tumors by Jungi, W F

Get more information

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B by Cavalli, F, Jungi, W F, Nissen, N I, Pajak, T F, Coleman, M, Holland, J F

“…In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of…”
Get more information

Neutrophil migration in health and disease by Senn, H J, Jungi, W F

Get more information

Etoposide as single agent and in combination with cis-platinum for malignant lymphomas by Kroner, T, Obrecht, J P, Jungi, W F

Get more information

Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung by JOSS, R. A, OBRECHT, J.-P, JUNGI, W. F, ALBERTO, P, SAUTER, C, CAVALLI, F

“…Twenty-five patients with measurable small cell lung cancer relapsing after first-line chemotherapy were treated with vindesine 3 mg/m2 IV on days 1 and 8 and…”
Get full text

A phase II study of doxifluridine in patients with advanced breast cancer by Alberto, P, Jungi, W F, Siegenthaler, P, Mermillod, B, Obrecht, J P, Decoster, G, Cavalli, F

Get more information